Clinuvel Pharmaceuticals (CUV) H1 2025 earnings summary

Executive summary

• Achieved record underlying profit and double-digit revenue growth for H1 FY2025, driven by increased patient treatment, SCENESSE® expansion, and controlled expenses.

• Treated more patients and distributed more SCENESSE® implants than any previous first half, with expansion of North American Specialty Centers to 93 and further growth planned.

• Declared and paid seventh consecutive dividend following FY2024 results.

• Board renewal with three new Non-Executive Directors and clinical team restructuring.

• Business model leverages direct distribution, long-term prescriber relationships, and rare disease infrastructure.

Financial highlights

• Total revenue for H1 FY2025 was $43.3 million, up 21.1% year-over-year, with commercial sales up 10.5% and interest income up 26.1%.

• Profit before tax rose 48.1% to $21.9 million; profit after tax increased 28.7% to $14.1 million.

• Basic earnings per share increased 27.4% to $0.28.

• Cash and term deposits reached $198.2 million, up 7.8% from June 2024; net assets increased 7% to $217.3 million.

• Net profit before tax margin was 50.7% of revenue; net profit after tax margin 32.5%.

Outlook and guidance

• Ongoing revenue growth expected, underpinned by increased patient numbers, high retention, adolescent treatment, higher dose frequency in Europe, and expansion into new jurisdictions.

• Expansion to 120 North American Specialty Centers targeted; awaiting EMA and Health Canada decisions on SCENESSE® and label variation.

• Completion of CUV105 vitiligo study recruitment targeted for June 2025; CUV107 study to commence; launch of next-generation CYACÊLLE and further milestones expected in 2025.

• Expenses anticipated to rise as investment continues in late-stage Vitiligo and other clinical programs.

• No forward revenue guidance provided, but confidence in continued growth.